First Time Loading...

Adverum Biotechnologies Inc
NASDAQ:ADVM

Watchlist Manager
Adverum Biotechnologies Inc Logo
Adverum Biotechnologies Inc
NASDAQ:ADVM
Watchlist
Price: 10.43 USD 4.3% Market Closed
Updated: May 4, 2024

Adverum Biotechnologies Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adverum Biotechnologies Inc
Operating Income Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Adverum Biotechnologies Inc
NASDAQ:ADVM
Operating Income
-$123.8m
CAGR 3-Years
-2%
CAGR 5-Years
-11%
CAGR 10-Years
-43%
Abbvie Inc
NYSE:ABBV
Operating Income
$16.6B
CAGR 3-Years
8%
CAGR 5-Years
7%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$8.7B
CAGR 3-Years
24%
CAGR 5-Years
1%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Operating Income
$8.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$3.8B
CAGR 3-Years
10%
CAGR 5-Years
42%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
19%

See Also

What is Adverum Biotechnologies Inc's Operating Income?
Operating Income
-123.8m USD

Based on the financial report for Dec 31, 2023, Adverum Biotechnologies Inc's Operating Income amounts to -123.8m USD.

What is Adverum Biotechnologies Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-43%

Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for Adverum Biotechnologies Inc have been -2% over the past three years , -11% over the past five years , and -43% over the past ten years .